Summary of Acumen Pharmaceuticals Q2 2026 Earnings Call

1Key Financial Results and Metrics

Cash Position: Ended Q2 2026 with $110.2 million in cash and marketable securities, expected to fund operations into early 2027.

Expenses:

R&D expenses were $27.8 million, a decrease from the previous year due to lower manufacturing and CRO costs.

G&A expenses were stable at $4.7 million.

Losses: Reported a loss from operations of $32.6 million and a net loss of $32.7 million for the quarter.

2Strategic Updates and Business Highlights

Clinical Trials: Focused on advancing sabirnetug in the Phase II ALTITUDE-AD trial, with topline results expected late 2026. The trial aims to evaluate the efficacy of targeting synaptotoxic amyloid-beta oligomers in Alzheimer's patients.

New Candidates: Announced the nomination of two enhanced brain delivery (EBD) candidates (ACU301 and ACU401) for Alzheimer's treatment, leveraging blood-brain barrier penetration technology.

Patient Engagement: Highlighted strong engagement from patients and caregivers in ongoing studies, which is critical for trial success.

Investor Relations Day: Scheduled for September 16, 2026, to discuss the investment thesis and provide updates before the Phase II data release.

3Forward Guidance and Outlook

Anticipates topline results from the ALTITUDE-AD trial to include primary and secondary endpoints, safety assessments, and biomarker data.

Plans to file an IND for the lead EBD candidate by mid-2027.

The company remains optimistic about the potential of sabirnetug and its EBD program to provide differentiated treatment options for Alzheimer's patients.

4Bad News, Challenges, or Points of Concern

Competitive Landscape: Competitors are also pursuing oligomer-specific approaches, which could impact market positioning. Concerns were raised regarding how emerging data from competitors might influence expectations for sabirnetug.

Regulatory Engagements: While preparations for Phase III are underway, specific regulatory interactions regarding trial design are still pending.

Market Risks: The company faces risks related to the efficacy and safety of its treatments, especially as it approaches the critical data readout from ALTITUDE-AD.

5Notable Q&A Insights

Safety and Efficacy Expectations: Management expressed confidence in sabirnetug's safety profile, citing its IgG2 antibody format and selective targeting of oligomers as potential advantages over existing treatments.

Biomarker Data: Confirmed that biomarker data will be included in the topline results, enhancing the robustness of the study's findings.

Digital Twins Collaboration: Discussed a partnership with Unlearn.AI to utilize digital twins for patient modeling, which may refine patient selection and improve trial outcomes.

Next Steps for EBD Candidates: The company is evaluating which of the two EBD candidates to advance into clinical trials, with a focus on optimizing the product profile. Overall, Acumen Pharmaceuticals is positioned for a pivotal year with significant clinical milestones ahead, though it must navigate a competitive landscape and regulatory complexities.